<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="case-report" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Intractable Rare Dis Res</journal-id>
<journal-id journal-id-type="iso-abbrev">Intractable Rare Dis Res</journal-id>
<journal-id journal-id-type="publisher-id">irdr</journal-id>
<journal-id journal-id-type="hwp">irdr</journal-id>
<journal-title-group>
<journal-title>Intractable &amp; Rare Diseases Research</journal-title>
</journal-title-group>
<issn pub-type="ppub">2186-3644</issn>
<issn pub-type="epub">2186-361X</issn>
<publisher>
<publisher-name>International Research and Cooperation Association for Bio &amp; Socio-Sciences Advancement</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30881862</article-id>
<article-id pub-id-type="pmc">6409113</article-id>
<article-id pub-id-type="doi">10.5582/irdr.2018.01133</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Case Report</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A novel mutation in <italic>CACNA1A</italic> gene in a Saudi female with episodic ataxia type 2 with no response to acetazolamide or 4-aminopyridine </article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Algahtani</surname>
<given-names>Hussein</given-names>
</name>
<xref ref-type="aff" rid="a1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shirah</surname>
<given-names>Bader</given-names>
</name>
<xref ref-type="aff" rid="a2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Algahtani</surname>
<given-names>Raghad</given-names>
</name>
<xref ref-type="aff" rid="a3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Al-Qahtani</surname>
<given-names>Mohammad H.</given-names>
</name>
<xref ref-type="aff" rid="a4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Abdulkareem</surname>
<given-names>Angham Abdulrahman</given-names>
</name>
<xref ref-type="aff" rid="a4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Naseer</surname>
<given-names>Muhammad Imran</given-names>
</name>
<xref ref-type="aff" rid="a4">
<sup>4</sup>
</xref>
</contrib>
<aff id="a1">
<label>1</label> King Abdulaziz Medical City/King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia;</aff>
<aff id="a2">
<label>2</label> King Abdullah International Medical Research Center/King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia;</aff>
<aff id="a3">
<label>3</label> King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia;</aff>
<aff id="a4">
<label>4</label> Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia.</aff>
</contrib-group>
<author-notes>
<corresp id="c1"><label>*</label><italic>Address correspondence to:</italic>Dr. Hussein Algahtani, King Abdulaziz Medical City/King Saud bin Abdulaziz University for Health Sciences, P.O. Box: 12723, Jeddah 21483, Saudi Arabia. Contact No.: 00966556633130. E-mail: <email>halgahtani@hotmail.com</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>2</month>
<year>2019</year>
</pub-date>
<volume>8</volume>
<issue>1</issue>
<fpage>67</fpage>
<lpage>71</lpage>
<history>
<date date-type="received">
<day>8</day>
<month>12</month>
<year>2018</year>
</date>
<date date-type="rev-recd">
<day>20</day>
<month>2</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>24</day>
<month>2</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>2019, International Research and Cooperation Association for Bio &amp; Socio - Sciences Advancement</copyright-statement>
<copyright-year>2019</copyright-year>
</permissions>
<abstract>
<title>Summary</title>
<p>Episodic ataxia is a genetically heterogeneous neurological condition characterized by spells of incoordination and imbalance, often associated with progressive ataxia. Episodic ataxia type 2, caused by calcium voltage-gated channel subunit alpha1 A (CACNA1A MIM: 601011) mutation, is the most common form of episodic ataxia. It is characterized by recurrent attacks of imbalance associated with interictal nystagmus lasting hours to days and triggered by emotional stress or exercise. In this article, we report a novel heterozygous intronic variant c.5743+14A&gt;G in the <italic>CACNA1A</italic> gene in a Saudi family. To the best of our knowledge, this variant has not been described in the literature or reported in public mutation databases. This report indicated that acetazolamide is not beneficial, and it may be even harmful to patients with episodic ataxia type 2 if used in later stages. In addition, treatment with 4-aminopyridine did not show any efficacy to improve walking or balance in our patient, which indicates the importance of early initiation of therapy before the later stages of the disease. Further research is needed to explore potential treatments for this challenging disease.</p>
</abstract>
<kwd-group kwd-group-type="author">
<kwd>
<italic>CACNA1A</italic>
</kwd>
<kwd>alpha-1A subunit</kwd>
<kwd>autosomal dominant cerebellar ataxia</kwd>
<kwd>novel Mutation</kwd>
<kwd>Saudi Arabia</kwd>
</kwd-group>
<counts>
<fig-count count="3"></fig-count>
<table-count count="0"></table-count>
<ref-count count="24"></ref-count>
<page-count count="5"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>